Ocular Pharmacology for Scleritis: Review of Treatment and a Practical Perspective.
Publication/Presentation Date
5-1-2017
Abstract
Scleritis is defined as an infectious or noninfectious inflammation of the sclera that can be broadly categorized according to anatomic location (ie, anterior or posterior) and whether the process is necrotizing or non-necrotizing. Treatment for scleritis is dictated by the etiology of the inflammation, with infectious forms requiring treatment of the inciting agent and noninfectious forms requiring treatment of the underlying inflammation with immunosuppression. Pharmacotherapy for noninfectious scleritis can be classified according to delivery route (eg, local or systemic) and mechanism of action (eg, biologic or nonbiologic). This review will briefly summarize the classification scheme for scleritis before reviewing in depth both systemic and local pharmacotherapies that can be used to effectively treat an eye afflicted by either infectious or noninfectious scleritis. Traditional anti-inflammatory agents such as nonsteroidal anti-inflammatory drugs, steroids, and immunomodulatory therapy will be discussed, as well as newer biologic therapies such as antitumor necrosis factor alpha and anti-CD20 agents.
Volume
33
Issue
4
First Page
240
Last Page
246
ISSN
1557-7732
Published In/Presented At
Stem, M. S., Todorich, B., & Faia, L. J. (2017). Ocular Pharmacology for Scleritis: Review of Treatment and a Practical Perspective. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 33(4), 240–246. https://doi.org/10.1089/jop.2016.0127
Disciplines
Medicine and Health Sciences
PubMedID
28355124
Department(s)
Department of Medicine
Document Type
Article